Vaxcyte, Inc. (PCVX)
NASDAQ · Manufacturing · Biological products, (no diagnostic substances)
$56.26−$0.6400 (−1.12%) on the dayAs of the close; data may be delayed.
PCVX price, last 12 months
Key stats
- Previous close
- $56.90
- Open
- $56.80
- Day range
- $55.92 – $57.50
- 52-week range
- $31.89 – $65.00
- Volume
- 753.4K
- Avg volume (20 days)
- 1.4M
- Market cap
- $8.4B
Performance
1W−3.2%
1M−7.9%
3M−0.5%
6M+2.8%
YTD+21.9%
1Y+71.4%
vs S&P 500, 1Y+54.6 pts
Technicals and fundamentals
About Vaxcyte, Inc.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.
- Sector
- Manufacturing
- Industry
- Biological products, (no diagnostic substances)
- Listed on
- NASDAQ
- Market cap
- $8.4B